Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitors: Implications for stem cell mitosis and centrosome dynamics

Stem Cell Research

Volumn 13, Issue 1, 2014, Pages 135-143

  Mannino, Mariella ^a   Gomez Roman, Natividad ^b   Hochegger, Helfrid ^a   Chalmers, Anthony J ^b  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALISERTIB; AURORA A KINASE; ENZYME INHIBITOR; POLO LIKE KINASE 1; AZEPINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ARTICLE; ASYMMETRIC CELL DIVISION; CELL DIFFERENTIATION; CELL DIVISION; CELL SURVIVAL; CENTROSOME; DRUG SENSITIVITY; DRUG TARGETING; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LOW DRUG DOSE; MITOSIS; MITOSIS SPINDLE; MOUSE; NONHUMAN; POLYPLOIDY; PRIORITY JOURNAL; SENESCENCE; SPINDLE CELL; STEM CELL; XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CANCER STEM CELL; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENETICS; HELA CELL LINE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; AURORA KINASE A; AZEPINES; BRAIN NEOPLASMS; CELL LINE, TUMOR; CENTROSOME; GLIOBLASTOMA; HELA CELLS; HUMANS; MICE; MITOSIS; NEOPLASTIC STEM CELLS; POLYPLOIDY; PROTEIN KINASE INHIBITORS; PYRIMIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901456358     PISSN: 18735061     EISSN: 18767753     Source Type: Journal    
DOI: 10.1016/j.scr.2014.05.001     Document Type: Article

References (32)

1. Barton V.N., et al. Aurora kinase A as a rational target for therapy in glioblastoma. J. Neurosurg. Pediatr. 2010, 6:98-105.
2. Beier D., Schulz J.B., Beier C.P. Chemoresistance of glioblastoma cancer stem cells-much more complex than expected. Mol. Cancer 2011, 10:128.
3. Cammareri P., et al. Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res. 2010, 70:4655-4665.
4. Chefetz I., Holmberg J.C., Alvero A.B., Visintin I., Mor G. Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFkB pathway. Cell Cycle 2011, 10:2206-2214.
5. Chen J., et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488:522-526.
6. Coppe J.P., et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008, 6:2853-2868.
7. Fael Al-Mayhani T.M., et al. An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours. J. Neurosci. Methods 2009, 176:192-199.
8. Gorgun G., et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010, 115:5202-5213.
9. Harrison M.R., Holen K.D., Liu G. Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin. Adv. Hematol. Oncol. 2009, 7:54-64.
10. Hegarat N., et al. Aurora A and Aurora B jointly coordinate chromosome segregation and anaphase microtubule dynamics. J. Cell Biol. 2011, 195:1103-1113.
11. Huck J.J., et al. MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol. Cancer Res. 2010, 8:373-384.
12. Krajcovic M., Overholtzer M. Mechanisms of ploidy increase in human cancers: a new role for cell cannibalism. Cancer Res. 2012, 72:1596-1601.
13. Lathia J.D., et al. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis. 2011, 2:e200.
14. Lee C., et al. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice. Stem Cells 2012, 30:1064-1075.
15. Lehman N.L., et al. Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas. Cell Cycle 2012, 11:489-502.
16. Liu Y., et al. Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-kappaB impairs this drug-induced senescence. EMBO Mol. Med. 2013, 5:149-166.
17. Loh J.K., et al. Differential expression of centrosomal proteins at different stages of human glioma. BMC Cancer 2010, 10:268.
18. Manfredi M.G., et al. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin. Cancer Res. 2011, 17:7614-7624.
19. Morrison S.J., Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006, 441:1068-1074.
20. Nair J.S., Ho A.L., Schwartz G.K. The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent. Cell Cycle 2012, 11:807-817.
21. Nigg E.A., Stearns T. The centrosome cycle: centriole biogenesis, duplication and inherent asymmetries. Nat. Cell Biol. 2011, 13:1154-1160.
22. Overholtzer M., et al. A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion. Cell 2007, 131:966-979.
23. Pallini R., et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin. Cancer Res. 2008, 14:8205-8212.
24. Rodier F., Campisi J. Four faces of cellular senescence. J. Cell Biol. 2011, 192:547-556.
25. Roninson I.B. Tumor cell senescence in cancer treatment. Cancer Res. 2003, 63:2705-2715.
26. Strojnik T., Rosland G.V., Sakariassen P.O., Kavalar R., Lah T. Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg. Neurol. 2007, 68:133-143. (discussion 143-4).
27. Stupp R., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10:459-466.
28. Wang H., et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 2009, 27:2393-2404.
29. Wang Q., et al. Polyploidy road to therapy-induced cellular senescence and escape. Int. J. Cancer 2013, 132:1505-1515.
30. Yamashita Y.M., Mahowald A.P., Perlin J.R., Fuller M.T. Asymmetric inheritance of mother versus daughter centrosome in stem cell division. Science 2007, 315:518-521.
31. Zeppernick F., et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 2008, 14:123-129.
32. Zhang M., et al. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J. Exp. Clin. Cancer Res. 2008, 27:85.